The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALPMY Detailed Price Forecast - CNN Money||View ALPMY Detailed Summary - Google Finance|
|View ALPMY Detailed Summary - Yahoo! Finance||View ALPMY Stock Research & Analysis - Zacks.com|
|View ALPMY Trends & Analysis - Trade-Ideas||View ALPMY Major Holders - Barrons|
|View ALPMY Call Transcripts - NASDAQ||View ALPMY Breaking News & Analysis - Seeking Alpha|
|View ALPMY Annual Report - CompanySpotlight.com||View ALPMY OTC Short Report - OTCShortReport.com|
|View ALPMY Fundamentals - TradeKing||View ALPMY SEC Filings - Bar Chart|
|View Historical Prices for ALPMY - The WSJ||View Performance/Total Return for ALPMY - Morningstar|
|View the Analyst Estimates for ALPMY - MarketWatch||View the Earnings History for ALPMY - CNBC|
|View the ALPMY Earnings - StockMarketWatch||View ALPMY Buy or Sell Recommendations - MacroAxis|
|View the ALPMY Bullish Patterns - American Bulls||View ALPMY Short Pain Metrics - ShortPainBot.com|
|View ALPMY Stock Mentions - StockTwits||View ALPMY Stock Mentions - PennyStockTweets|
|View ALPMY Stock Mentions - Twitter||View ALPMY Investment Forum News - Investor Hub|
|View ALPMY Stock Mentions - Yahoo! Message Board||View ALPMY Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALPMY - SECform4.com||View Insider Transactions for ALPMY - Insider Cow|
|View ALPMY Major Holdings Summary - CNBC||View Insider Disclosure for ALPMY - OTC Markets|
|View Insider Transactions for ALPMY - Yahoo! Finance||View Institutional Holdings for ALPMY - NASDAQ|
|View ALPMY Stock Insight & Charts - FinViz.com||View ALPMY Investment Charts - StockCharts.com|
|View ALPMY Stock Overview & Charts - BarChart||View ALPMY User Generated Charts - Trading View|
Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company
Posted on Wednesday April 18, 2018
TOKYO, April 18, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, "Astellas" ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan, "Kite"), today announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite. The asset transfer was completed on April 12, 2018.
Updates on AbbVie’s AndroGel, Lupron, and Kaletra
Posted on Tuesday April 17, 2018
In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.
Understanding FibroGen’s Research Pipeline
Posted on Friday April 06, 2018
FibroGen (FGEN) is capitalizing on its extensive experience in fibrosis and hypoxia-inducible factor (or HIF) biology to advance a pipeline targeted for the treatment of anemia, fibrotic disease, cancer, and corneal blindness. Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200. FG-3019 is a fully human monoclonal antibody that inhibits the activity of connective tissue growth factor.
TOKYO and BOTHELL, Wash., March 26, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics, Inc. (SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI). Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.